Updates are available Correction dated 2021-08-26
Click to view Correction: https://doi.org/10.1186/s10194-021-01307-6
-
Authors
Ament, Michael
Day, Kathleen http://orcid.org/0000-0002-6234-0065
Stauffer, Virginia L
Skljarevski, Vladimir
Rettiganti, Mallikarjuna
Pearlman, Eric
Aurora, Sheena K.
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 26 October 2020
Accepted: 27 January 2021
First Online: 6 February 2021
Change Date: 26 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s10194-021-01307-6
Ethics approval and consent to participate
: These studies were approved by the appropriate institutional review board for each of the study sites. They were all conducted according to Good Clinical Practice and the Declaration of Helsinki guidelines. All patients gave written informed consent to participate in the study.
: Not applicable.
: KD, VLS, VS, MR, and EP are full time employees and minor stockholders of Eli Lilly and Company. SKA is a former employee of Eli Lilly and Company. MA is a consultant for Eli Lilly and Company, BioHaven, and Impel, and is on speaker bureaus for Allergan/AbbVie, Amgen Inc., BioHaven Pharmaceuticals, electroCore Inc., Eli Lilly and Company, Alder/Lundbeck, and Teva Pharmaceuticals Industries.
